Breast cancer resistance protein (BCRP) and excision repair cross complement-1 (ERCC1) expression in esophageal cancers and response to cisplatin and irinotecan based chemotherapy.
about
Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression.[Synergistic Antitumor Effect of Amorphigenin Combined with Cisplatin in Human Lung Adenocarcinoma A549/DDP Cells].ABC Transporters and Their Role in the Neoadjuvant Treatment of Esophageal Cancer.A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomasConstitutional mismatch repair-deficiency: current problems and emerging therapeutic strategies
P2860
Breast cancer resistance protein (BCRP) and excision repair cross complement-1 (ERCC1) expression in esophageal cancers and response to cisplatin and irinotecan based chemotherapy.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Breast cancer resistance prote ...... irinotecan based chemotherapy.
@ast
Breast cancer resistance prote ...... irinotecan based chemotherapy.
@en
type
label
Breast cancer resistance prote ...... irinotecan based chemotherapy.
@ast
Breast cancer resistance prote ...... irinotecan based chemotherapy.
@en
prefLabel
Breast cancer resistance prote ...... irinotecan based chemotherapy.
@ast
Breast cancer resistance prote ...... irinotecan based chemotherapy.
@en
P2093
P2860
P1476
Breast cancer resistance prote ...... irinotecan based chemotherapy.
@en
P2093
Anubha Bharthuar
Charles Levea
Jennifer D Black
Renuka Iyer
Sana Saif Ur Rehman
Terry L Mashtare
Usha Malhotra
P2860
P304
P356
10.3978/J.ISSN.2078-6891.2014.018
P577
2014-08-01T00:00:00Z